A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Response Pharmaceuticals, Inc., a clinical-stage company focused on weight management and metabolic health in high-risk populations, today announced the early completion of enrollment in a Phase 2 ...

A live webcast of the event will be available on the investor relations page of the Terns Pharmaceuticals website at https://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ ...

Discover how modern diabetes medications offer cardiovascular benefits, transforming diabetes care and improving outcomes worldwide.

Certain diabetes medications may have additional health benefits for older adults, scientists from the University of Glasgow ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

INNOVENT BIO (01801.HK)'s total product revenue for 2024 amounted to more than RMB8.2 billion, representing a robust YoY ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Equillium, Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and ...